-
CSR Summary Not Yet Available
-
NCT03412565
-
Primary Citation Trial has yet to be published
-
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameDaratumumabProduct NameDARZALEX®Therapeutic AreaCancers and Other NeoplasmsEnrollment265% Female40.4%% White66.8%
Product ClassMonoclonal AntibodySponsor Protocol Number54767414MMY2040Data PartnerJohnson & JohnsonCondition StudiedMultiple MyelomaMean/Median Age (Years)65
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available